Dementia: from muddled diagnoses to treatable mechanisms

Brain

Volumn 136, Issue 9, 2013, Pages 2652-2654

  Hachinski, Vladimir ^a   Sposato, Luciano A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TAR DNA BINDING PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DEMENTIA; DSM-III; HUMAN; ICD-10; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NOTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 84883377373     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt230     Document Type: Note

References (16)

1. Akbarian S, Beeri MS, Haroutunian V. Epigenetic determinants of healthy and diseased brain aging and cognition. JAMA Neurol 2013; 70: 711-18.
2. Akinyemi R, Mukaetova-Ladinska E, Attems J, Attems J, Ihara M, Kalaria RN. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Curr Alzheimer Res 2013; 10: 642-53.
3. Bowler JV, Munoz DG, Merskey H, Hachinski V. Factors affecting the age of onset and rate of progression of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1998; 65: 184-90.
4. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997; 337: 1667-74.
5. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994; 51: 888-95.
6. Hachinski V. Vascular dementia: a radical redefinition. Dementia 1994; 5: 130-2.
7. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006; 37: 2220-41.
8. Hooshmand B, Polvikoski T, Kivipelto M, Tanskanen M, Myllykangas L, Erkinjuntti T, et al. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain 2013; 136: 2707-16.
9. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med 2013; 54: 1011-13.
10. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143-53.
11. Noel-Storr AH, Flicker L, Ritchie CW, Nguyen GH, Gupta T, Wood P, et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimers Dement 2013; 9: e96-105.
12. Paulson HL, Igo I. Genetics of dementia. Semin Neurol 2011; 31: 449-60.
13. Ta R, Suchy M, Tam JH, Li AX, Martinez-Santiesteban FS, Scholl TJ, et al. A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin-D detection. Contrast Media Mol Imaging 2013; 8: 127-39.
14. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013; 136: 2697-706.
15. Wald DS, Kasturiratne A, Simmonds M. Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers Dement 2011; 7: 412-7.
16. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723-38.